Did Pfizer Overpay For Yet Another Acquisition? (Archive)
Pfizer’s Metsera obesity deal looks reasonably priced, but fundamentals still justify only a hold.
This 5-Minute Pitch was originally published on Seeking Alpha before the launch of the Hunting Alphas website. It is shared here to showcase my previous work and track record. New 5-Minute Pitches published on this site will not be disseminated anywhere else.
Elevator Pitch
- After Pfizer failed to crack the obesity management drug market organically, I feared that it might resort to an overpriced M&A.
- As expected, PFE is entering the obesity drug market via an acquisition. But I am pleasantly surprised to see that the valuation it paid for this M&A is rather reasonable.
- To avoid tariff hits, Pfizer is trying to stay on the good side of the United States. But this is coming at the cost of FCF and margin hits.
- PFE stock looks undervalued vs. pharmaceutical peers. But a weak earnings growth outlook may justify its relatively discounted valuations.
- Technical analysis shows seller momentum slowing, but no convincing buyer activity yet to signal a trend reversal.
Read the full article here.
Disclosures and Disclaimers
Past performance ≠ future results. Not investment advice. See full Disclaimer.
Comments ()